SCNI News and Press, Scanner Technologies Corp From 05/16/24

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through i...

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update PR Newswire JERUSALEM , May 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical c...

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a sta...

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal PR Newswire The Board has Approved a Ratio Change of the ADSs to Non-traded Ordinary Shares (equivalent to a reverse split) Designed to Regain Compliance JERUSALEM , May 6, 20...

Vitamin D plays different roles and is easily available through the sun, meat and plants. Despite this, many individuals are vitamin D deficient. Different studies have looked into the use of vitamin D for the prevention and treatment of different cancers, including bowel, breast, skin and pro...

Pancreatic cancer is a challenging cancer to treat. Research shows that roughly 12% of individuals diagnosed with this particular cancer live beyond five years. Additionally, treatments such as chemotherapy, immunotherapy and targeted therapies are unsuccessful in treating pancreatic cancer. P...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through i...

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG PR Newswire JERUSALEM , April 10, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Sc...

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services PR Newswire JERUSALEM , April 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd...